ISARIC4C (Coronavirus Clinical Characterisation Consortium)

We are a UK-wide consortium of doctors and scientists committed to answering urgent questions about COVID-19 quickly, openly, and for the benefit of all. Over the last 9 years we have been preparing for such a major outbreak worldwide International Severe Acute Respiratory Infection Consortium Clinical Characterisation Protocol; our team deployed immediately and has been collecting data and samples since the first cases were reported in the UK.


We have recruited:

  • 207094 patients at Tier Zero case report forms(CO-CIN)
  • 2309 patients at Tier 1/2 (host/viral multiomics)
  • 12591 critically-ill patients can also be recruited to a sister study, the ISARIC GenOMICC study

Analysis Platform

The ISARIC4C study has created an open-access integrated analysis platform for linked clincal data from across the NHS for a range of studies, including ISARIC4C, GenOMICC, PHOSP, COG-UK and UK-CIC.

Consortium details


ISARIC4C is funded by two major awards from UK Reasearch and Inovation (UKRI) and The National Institute For Health Research (NIHR). A grant from UKRI Medical Research Council with a total value of £5.9M to JK Baillie (PI), University of Edinburgh; MG Semple, University of Liverpool; and P Openshaw, Imperial College London (co-leads). Full list of investigators and specific deliverables. A grant from NIHR with a current value of £8.9M to MG Semple (CI), University of Liverpool; AD Docherty, University of Edinburgh, and CA Green, University of Birmingham. We share data and samples to get answers as fast as possible. We will not end this outbreak sitting on a biobank; our intention is to use every drop of every sample, now, to have the biggest possible impact on the COVID-19 crisis. Any investigators with the ability to contribute can access our data and samples. The ISARIC4C study provides a foundation for other studies, such as clinical trials of new treatments, to help better understand the best way to use interventions.


Risk prediction: the 4C Mortality Score

BMJ 9 Mar 2020 The ISARIC 4C Mortality Score DOI: 10.1136/bmj.m3339 Using data from 57, 824 hos...

T cell activation

Nature Immunology (4th September 2020) Immune cells target many different parts of the virus ...

Characterisation of hospitalised cases of COVID-19

BMJ: 2020; 369 Quantifying the problem Within weeks of being funded, we produced the largest st...

Impact on children

BMJ 2020;370:m3249 Clinical characterisation of Covid-19 in children We have comprehensively ch...

Symptom clusters

MedRxiv August 16th 2020. Because of the large scale of the ISARIC-4C study, we were able to d...


SSRN July 2020 Impact of ethnicity We have carefully studied the effect of ethnicity on outcome...


MedRxiv September 2020; Nature online December 2020 Genetic mechanisms of severe Covid-19 In co...

Testing the tests

MedRxiv May 2020 We proposed and established a Diagnostic Evaluation Platform at the University ...

ICECAP autopsy study

MedRxiv June 2020 Supporting autopsy work ISARIC 4C resources and consortium partners supported...

Remdesivir Statistical Analysis Plan

The Remdesivir Statistical Analysis Plan was approved on 16 December 2020.

Setting Serology Standards

Setting the standard ISARIC 4C defined the international reference standard for SARS-CoV-2 serol...


Medrxiv June 2020 Transmission dynamics of COVID-19 We have explored the mechanisms of viral tr...